Diabetes monitoring systems for people with type 1 diabetes, type 2 diabetes, diabetes in pregancy addressing advisory systems for artificial pancreas research and patient engagement for continuous glucose monitoring (CGM). Invented the IoT in the field of diabetes sensors and biometrics in 2001.
Evidence Base
According to a comparison of two studies published in the print edition of "Diabetes Care" in early 2012, frequent pattern management (review of spot blood sugar measurements for trends) made possible by specialized handheld cellular devices, advances in wireless networks and mobile health technology (ie - GlucoMON®-ADMS by Diabetech, LP) delivers superior results compared to either:
​
-
Conventional Self Monitoring of Blood Glucose (SMBG) - based on analysis of the recently published ADMS study conducted by the Morris Lichtenstein Medical Research Foundation (Published online before print February 1, 2012, doi:10.2337/dc11-1597 Diabetes Care February 1, 2012)
​
-
Continuous Glucose Monitoring systems (CGM/CGMS) - based on analysis of the recently published CGM study conducted by DirecNet (Published online before print; December 30, 2011, doi:10.2337/dc11-1746 Diabetes Care February 2012vol. 35 no. 2 204-210).
From the ADMS study:
​
OBJECTIVE: The study objective was to evaluate how the use of a pervasive blood glucose
monitoring (BGM) technology relates to glycemic control, report of self-care behavior, and
emotional response to BGM of children with type 1 diabetes and their parents.
SUMMARY: Using the ADMS 1–3 times/week correlates directly to clinically significant improvement in overall blood sugar control as measured by A1c compared to standard care in children with type 1 diabetes (-0.9 HbA1c; p-value = 0.04). Further, families engaged in at least weekly use of ADMS demonstrated clinically significant improvement in diabetes self-management skills without increase in stress on the child or family caregivers.
​
SIGNIFICANCE TO THE FIELD OF DIABETES CARE: For the first time, FREQUENT PATTERN MANAGEMENT was proven via randomized controlled clinical trial as a method for clinically significant improvement in overall blood sugar control as measured by A1c.
This trial proves that GlucoMON-ADMS is effective as an enabling technology and method making it possible and practical for literally anyone with diabetes to perform frequent and long term (at least one year) pattern management ON THEIR OWN without burdening their health care team. ADMS stands alone with an evidence base as an enabling technology for improving and sustaining those improvements in the field of patient self-care. No other technology or system has ever been able to deliver a similar result.
A similar study in 2009-2011 utilizing ADMS was conducted by the State of Texas Health & Human Services Commission involving more than 1,500 of their adult type 2 Medicaid enrolled beneficiaries with previously diagnosed type 2 diabetes. Results from this study are available for review and present the business case for automated blood sugar data collection as a requirement for remote diabetes care delivery.
​
To read up on all of the Diabetech research please go to the clinical trials page.